125 related articles for article (PubMed ID: 38207253)
1. Erratum: The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
J Clin Oncol; 2024 Mar; 42(7):862. PubMed ID: 38207253
[No Abstract] [Full Text] [Related]
2. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Diefenbach CS; Li H; Hong F; Gordon LI; Fisher RI; Bartlett NL; Crump M; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ; Advani RH
Br J Haematol; 2015 Nov; 171(4):530-8. PubMed ID: 26343802
[TBL] [Abstract][Full Text] [Related]
3. A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma.
Tao Y; Chen H; Zhou Y; He X; Qin Y; Liu P; Zhou S; Yang J; Zhou L; Zhang C; Yang S; Gui L; Shi Y
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e486-e494. PubMed ID: 35238169
[TBL] [Abstract][Full Text] [Related]
4. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
[TBL] [Abstract][Full Text] [Related]
5. Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin-lymphoma.
Asimakopoulos JV; Angelopoulou MK; Arapaki MP; Kanellopoulos A; Dimou M; Giakoumis X; Konstantinou E; Belia M; Chatzidimitriou C; Sachanas S; Iliakis T; Kyrtsonis MC; Siakantaris MP; Viniou NA; Variamis E; Kontopidou FN; Pangalis GA; Panayiotidis P; Konstantopoulos K; Vassilakopoulos TP
Br J Haematol; 2020 Sep; 190(6):e335-e339. PubMed ID: 32602960
[No Abstract] [Full Text] [Related]
6. Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.
Hayden AR; Lee DG; Villa D; Gerrie AS; Scott DW; Slack GW; Sehn LH; Connors JM; Savage KJ
Br J Haematol; 2020 Apr; 189(1):122-127. PubMed ID: 31822034
[TBL] [Abstract][Full Text] [Related]
7. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Guisado-Vasco P; Arranz-Saez R; Canales M; Cánovas A; Garcia-Laraña J; García-Sanz R; Lopez A; López JL; Llanos M; Moraleda JM; Rodriguez J; Rayón C; Sabin P; Salar A; Marín-Niebla A; Morente M; Sánchez-Godoy P; Tomás JF; Muriel A; Abraira V; Piris MA; Garcia JF; Montalban C;
Leuk Lymphoma; 2012 May; 53(5):812-9. PubMed ID: 22185637
[TBL] [Abstract][Full Text] [Related]
8. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
Biggi A; Gallamini A; Chauvie S; Hutchings M; Kostakoglu L; Gregianin M; Meignan M; Malkowski B; Hofman MS; Barrington SF
J Nucl Med; 2013 May; 54(5):683-90. PubMed ID: 23516309
[TBL] [Abstract][Full Text] [Related]
9. Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma.
Mohite A; Rangarajan V; Goda J; Chugh S; Agrawal A; Sengar M
Asia Ocean J Nucl Med Biol; 2023; 11(2):111-121. PubMed ID: 37324230
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Clinical Outcomes in Patients with Newly Diagnosed Advanced-stage Hodgkin Lymphoma: A Nationwide Retrospective Study.
Jerry Teng CL; Tan TD; Pan YY; Lin YW; Lien PW; Chou HC; Chen PH; Lin FJ
Cancer Control; 2022; 29():10732748221124865. PubMed ID: 36134681
[TBL] [Abstract][Full Text] [Related]
11. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
12. Comments on the value International Prognostic Score (IPS), stage IV and age over 45 years, for the outcome of advanced Hodgkin lymphoma in chemotherapy containing adriamycin. The experience of the Spanish Hodgkin Lymphoma Study Group.
Guisado-Vasco P; Montalban C; García JF;
Br J Haematol; 2017 Jul; 178(2):336-338. PubMed ID: 27135208
[No Abstract] [Full Text] [Related]
13. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
16. Primary non-Hodgkin lymphoma of the large bowel.
Cho MJ; Ha CS; Allen PK; Fuller LM; Cabanillas F; Cox JD
Radiology; 1997 Nov; 205(2):535-9. PubMed ID: 9356641
[TBL] [Abstract][Full Text] [Related]
17. The Addition of Ferritin Enhanced the Prognostic Value of International Prognostic Index in Diffuse Large B-Cell Lymphoma.
Shen Z; Zhang S; Zhang M; Hu L; Sun Q; He C; Yan D; Ye J; Zhang H; Wang L; Gu W; Miao Y; Liu Q; Ouyang C; Zhu J; Wang C; Zhu T; Huang S; Sang W
Front Oncol; 2021; 11():823079. PubMed ID: 35127536
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy.
Moding EJ; Advani R; Rosenberg SA; Hoppe RT
Radiother Oncol; 2018 Dec; 129(3):507-512. PubMed ID: 30539763
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.
Kumar AJ; Nelson J; Rodday AM; Evens AM; Friedberg JW; Wildes TM; Parsons SK
J Geriatr Oncol; 2021 Nov; 12(8):1233-1239. PubMed ID: 34330667
[TBL] [Abstract][Full Text] [Related]
20. Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.
Kang J; Yoon S; Suh C
Blood Res; 2017 Dec; 52(4):276-284. PubMed ID: 29333404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
